Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab for Early-Stage MMR Deficient Endometrial Cancer
NCT06278857Phase 2Recruiting
- Sponsor
- Queensland Centre for Gynaecological Cancer Research
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in endometrial cancer (EC), sponsored by Queensland Centre for Gynaecological Cancer Research. Primary endpoint: Absence of endometrial cancer following protocol treatment regimen at Week 27. Started Aug 2024; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06278857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278857.